- PROFESSOR Medicine, Endocrinology, Diabetes and Bone Disease
American Board of Internal Medicine
MD, Sackler School of Medicine
Internship, Internal Medicine
Residency, Internal Medicine
Sheba Medical Center
Residency, Internal Medicine
Mount Sinai Hospital
Fellowship, Endoc & Metabolism
Mount Sinai Hospital
- Yaron Tomer, MD, FACP
Lillian and Henry M. Stratton Professor of Molecular Medicine
Chief, Division of Endocrinology, Diabetes and Bone Diseases
Dr. Yaron Tomer is Chief of the Division of Endocrinology, Diabetes and Bone Diseases at the Icahn School of Medicine at Mount Sinai’s Department of Medicine. Dr. Tomer received his medical degree from the Sackler School of Medicine at Tel Aviv University, Israel. He trained in Internal Medicine at Sheba Medical Center, Israel, and continued his training in Internal Medicine and in Endocrinology at The Mount Sinai Medical Center. Dr. Tomer stayed in Mount Sinai after his training, joining the faculty of the Division of Endocrinology in 1997. From 2005 to mid 2009, he joined the University Of Cincinnati College Of Medicine as Professor in the Department of Medicine. Dr. Tomer rejoined Mount Sinai School of Medicine in May of 2009 as Professor of Medicine and Vice Chairman of Medicine for Research. Dr. Tomer serves as an associate editor of the journal, Thyroid, and serves on the editorial boards of Edocrinology, the Journal of Clinical Endocrinology and Metabolism, and Autoimmunity Reviews, among others. He is a member of the American Society for Clinical Investigation and a Fellow of the American College of Physicians, as well as the American College of Endocrinology.
Etiology of autoimmune thyroiditis and diabetes
Postdoctoral Fellow: Angela Lombardi, Cheuk wun Li
Research Personnel: Erlinda Concepcion, Mihaela Stefan,
Summary of Research Studies:
The laboratory of Dr. Tomer studies the mechanisms leading to the development of autoimmune thyroiditis and diabetes. Current projects include: (1) Genetic and epigenetic studies in thyroid autoimmunity. The Tomer lab discovered that the presence of arginine at position 74 of the peptide binding groove of HLA-DR is critical for disease susceptibility. In collaboration with Dr. Osman's group from the Department Structural and Chemical biology they identified a specific HLA-DR pocket structure that is associated with thyroid autoimmunity. The group is now analyzing which immunogenic peptides can bind to these pockets and induce thyroid autoimmunity, since blocking these peptides from binding to the DR pockets can be used as a novel therapeutic approach. Dr. Tomer’s group also identified several non-MHC genetic polymorphisms that are associated with thyroid autoimmunity including variants in the CD40 and thyroglobulin genes. Current studies focus on the genetic and epigenetic mechanisms, by which these variants contribute to disease. The group is using tissue cultures to examine the effects of genetic variants on gene regulation and splicing, as well as transgenic and chimeric mouse models. (2) Genetic analysis of autoimmune (type 1) diabetes and thyroiditis. The Tomer lab is analyzing genes that confer shared susceptibility to the development of type 1 diabetes and autoimmune thyroiditis in the same individual. The lab has shown that the CTLA-4 and FOXP3 genes play a major role in this shared susceptibility and they are currently studying the mechanisms by which these genes predispose to both diseases. In addition the group is mapping additional genes conferring this shared susceptibility. (3) Environmental factors and thyroid autoimmunity. It is well known that certain infections, specifically hepatitis C, are associated with thyroid autoimmunity. In addition, interferon alpha therapy of hepatitis C can cause thyroiditis in a significant percentage of patients. Using tissue cultures and mouse models Dr. Tomer’s lab is studying the mechanisms by which hepatitis C infection, and interferon alpha therapy cause thyroiditis.
Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB, Owen R, Zhang W, Tomer Y. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proceedings of the National Academy of Sciences of the United States of America 2014 Aug;.
Employing a recombinant HLA-DR3 expression system to dissect MCH II-thyroglobulin peptide dynamism: A genetic, biochemical, and reverse immunolgical perspective. J Biol Chem 2009; 284: 34231-34243.
Tomer Y, Huber A. The etiology of autoimmune thyroid disease: A story of genes and enviroment. J Autoimm 2009; 32: 231-239.
Villano MJ, Huber AK, Greenberg DA, Golden BK, Concepcion E, Tomer Y. Autoimmune thyroiditis and diabetes: Dissecting the joint genetic susceptibility in a large cohort of multiplex families. J Clin Endocrinol Metab 2009; 94: 1458-1466.
Akeno N, Blackard JT, Tomer Y. HCV E2 protein binds directly to thyroid cells and induces IL-8 production: A new mechanism for HCV induced thyroid autoimmunity. J Autoimmun 2008; 31: 339-344.
Huber A, Menconi F, Corathers S, Jacobson EM, Tomer Y. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis; From epidemiology to mechanisms. Endocr Rev 2008; 29: 697-725.
Ban Y, Greenberg DA, Davies TF, Jacobson E, Concepcion E, Tomer Y. Linkage analysis of thyroid antibody production: Evidence for shared susceptibility to clinical autoimmune thyroid disease. J Clin Endocrinol Metab 2008; 93: 3589-3596.
Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, Davies TF, Ban Y, Jacobson EM, Concepcion ES, Li CW, Tomer Y. Molecular amino acid signatures in the MHC class II peptide binding pocket predispose to autoimmune thyroiditis in humans and in mice.. Proc Natl Acad Sci USA 2008; 105: 14034-14039.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Tomer did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Atran Berg Laboratory Building Floor 4 Room 38
1428 Madison Avenue
New York, NY 10029